Drug
Levocetirizine Dihydrochloride
Levocetirizine Dihydrochloride: highest development phase Post-Market, developed by Sanofi, UCB. 4 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Sanofi, UCB
Trials
| Drug | Phase | Indication |
|---|---|---|
| Levocetirizine dihydrochloride NCT00521131 | Post-Market | Rhinitis |
| XYZAL ALLERGY 24HR | Approved | |
| levocetirizine dihydrochloride NCT00524836 | Phase 3 | Rhinitis |
| Levocetirizine dihydrochloride NCT00521040 | Not Applicable | Rhinitis, Allergic, Seasonal |
Latest
Follow Levocetirizine Dihydrochloride on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.